Once-Daily Roflumilast Foam 0.3% Improves Severity and Burden of Itch in Patients With Scalp and Body Psoriasis in a Randomized, Double-blind, Vehicle-Controlled Phase 2b Study

Angela Moore; Javier  Alonso-Llamazares; Neal Bhatia; Alim Devani; Michael Bukhalo; Zoe Draelos; Melinda Gooderham; Steve Kempers; Leon  Kircik; Kim Papp; David Pariser; Marina Sankeva; Rodney  Sinclair; Matthew Zirwas; Amy  Feng; Patrick Burnett; Robert Higham; David Berk

doi:10.25251/skin.5.supp.43

Angela Moore

Arlington Research Center, Arlington, TX, Baylor University Medical Center, Dallas, TX, USA

Javier Alonso-Llamazares

Driven Research LLC, Coral Gables, FL, USA

Neal Bhatia

Therapeutics Clinical Research, San Diego, CA, USA

Alim Devani

Dermatology Research Institute and Probity Medical Research, Calgary, AB, Canada

Michael Bukhalo

Arlington Dermatology, Rolling Meadows, IL, USA

Zoe Draelos

Dermatology Consulting Services, PLLC High Point, NC

Melinda Gooderham

SkiN Centre for Dermatology, Probity Medical Research and Queen’s University, Peterborough, ON, Canada

Steve Kempers

Minnesota Clinical Study Center, Fridley, MN, USA

Leon Kircik

Mount Sinai

Kim Papp

Probity Medical Research, Waterloo, ON, Canada

David Pariser

Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA, USA

Marina Sankeva

Private Practice, Gabrovo, Bulgaria

Rodney Sinclair

Sinclair Dermatology, East Melbourne, Victoria, Australia

Matthew Zirwas

Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley, OH, USA

Amy Feng

Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA

Patrick Burnett

Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA

Robert Higham

Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA

David Berk

Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA

Keywords

roflumilast, foam, itch, psoriasis

Abstract

N/A

References

1. Chan CS, et al. J Am Acad Dermatol 2009;60:962-971.

2. Elewski B, et al. J Eur Acad Dermatol Venereol 2019;33:1465-1476.

3. Dopytalska K, et al. Reumatologia 2018;56:392-398.

4. Blakely K, Gooderham M. Psoriasis 2016;6:33-40.

5. Lebwohl MG, et al. N Engl J Med 2020;383:229-239

Poster PDF

Published

2021-11-05

DOI: https://doi.org/10.25251/skin.5.supp.43

How to Cite

[1]

2021. Once-Daily Roflumilast Foam 0.3% Improves Severity and Burden of Itch in Patients With Scalp and Body Psoriasis in a Randomized, Double-blind, Vehicle-Controlled Phase 2b Study. SKIN The Journal of Cutaneous Medicine. 5, 6 (Nov. 2021), s43. DOI:https://doi.org/10.25251/skin.5.supp.43.

Issue

Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)

Section

Poster Presentations from FC21 Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Joseph Merola, Milan Anadkat, Neal Bhatia, Tina Bhutani, Laura Ferris, Arash Mostaghimi, .Jason Guercio, Christian Thoma, Ming Tang, Mark Lebwohl, Spesolimab Use for Generalized Pustular Psoriasis Flare Prevention in Patients with Concomitant Plaque Psoriasis: Results from the Effisayil 2 Trial , SKIN The Journal of Cutaneous Medicine: Vol. 8 No. 2 (2024): March 2024 Issue
Richard Warren , April Armstrong , Melinda Gooderham, Bruce Strober , Diamant Thaci, Shinichi Imafuku, Howard Sofen, Lynda Spelman, Neil Korman, Min Zheng, Elizabeth Colston, John Throup , Sundeep Kundu, Renata Kisa, Subhashis Banerjee, Andrew Blauvelt, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Kristian Reich, Eric L Simpson, Richard Langley, Richard B Warren, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Le Gjerum, Anna Carlsson, Melinda Gooderham, Andreas Pinter, Marjolein de Bruin-Weller, Andrew Blauvelt, Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Jerry Bagel, Yipeng Wang, Paul Montgomery, III, Christian Abaya, Eric Andrade, Courtney Boyce, Tatiana Tomich, Byung-In Lee, David Pariser, Alan Menter, Tobin Dickerson, A Machine Learning-Based Test for Predicting Response to Psoriasis Biologics , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Todd Schlesinger, Leon Kircik, James Del Rosso, Darrell Rigel, Mark Lebwohl, Brian Berman, April Armstrong, Neal Bhatia, Vishal A. Patel, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Clinician- and Patient-Reported Outcomes with Tirbanibulin 1% Treatment for Actinic Keratosis in Routine Clinical Practice Across the U.S. (PROAK Study) , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 3 (2023): May Issue and Posters from WCH23 & WCM23
Richard B Warren, Kristian Reich, Eric L Simpson, Richard Langley, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Emilia Vacko, Melinda Gooderham, Mette Deleuran, Juan Francisco Silvestre, Stefan Weidinger, Andrew Blauvelt, 3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Emmy Graber, Hilary Baldwin, Julie C. Harper, Linda Stein Gold, Andrew F. Alexis, Richard G. Fried, Evan Rieder, James Del Rosso, Leon Kircik, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Adelaide Hebert, Investigator global assessment (IGA) of Acne Vulgaris and IGA Success among patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in community practices across the U.S: PROSES study analysis by gender and age , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Diamant Thaci, Kenneth Gordon , Melinda Gooderham, Bruce Strober , Neil Korman, Subhashis Banerjee, Subhashis Banerjee, Elizabeth Colston, Jonghyeon Kim, John Throup, Akimichi Morita, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Mark Lebwohl, Linda Stein Gold, Bruce Strober, April Armstrong, H Chih-Ho Hong, Leon Kircik, Jennifer Soung, Jeff Fromowitz, Scott Guenthner, Stephen Piscitelli, David Rubenstein, Philip Brown, Anna Tallman, Robert Bissonnette, Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Mark Lebwohl, Leon Kircik, Angela Moore, Linda Stein Gold, James Del Rosso, Zoe Draelos, Melinda Gooderham, Lawrence Green, Adelaide Herbert, Kim Papp, Jerry Bagel, Neal Bhatia, Laura Ferris, Terry Jones, Steve Kempers, David Pariser, Paul Yamauchi, Matthew Zirwas, Amy Feng, Patrick Burnett, Robert Higham, David Berk, Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)

1 2 3 4 5 6 7 8 9 10 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Most read articles by the same author(s)